As biotech stocks swing back into favor on Wall Street, here's a look at five picks that could deliver significant gains, according to analysts.
Following a tumultuous performance year, the biotechnology sector is steadily regaining traction once again, with investors starting to reveal a somewhat bullish sentiment despite having to endure macroeconomic...
The company reported a big jump in revenue and updated guidance.
HAMILTON, Bermuda, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that its management will participate in...
– ARCALYST® (rilonacept) net revenue of $27.0 million in Q2 2022 – – ARCALYST full-year 2022 net revenue expected to be $115 - $130 million – – Upfront...
– Kiniksa to receive $100 million in upfront and near-term payments – – Kiniksa is eligible to receive development and commercial milestones as well as...
HAMILTON, Bermuda, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and...
– ARCALYST® (rilonacept) net revenue of $22.2 million in Q1 2022 – – ARCALYST full-year 2022 net revenue expected to be $115 - $130 million – – Cash...
HAMILTON, Bermuda, May 02, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and...
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Kiniksa Pharmaceuticals Ltd , where a total volume of 1,222 contracts has been traded...